Transcatheter Mitral Valve Implantation With the FORTIS Device: Insights Into the Evaluation of Device Success

  • Abdul-Jawad Altisent O
  • Dumont E
  • Dagenais F
 et al. 
  • 8

    Readers

    Mendeley users who have this article in their library.
  • 4

    Citations

    Citations of this article.

Abstract

A 66-year old man with severe functional mitral regurgitation secondary to chronic ischemic cardiomyopathy (previous myocardial infarction and coronary artery bypass grafting) and advanced heart failure (left ventricular ejection fraction: 25%; New York Heart Association [NYHA] functional class III) was considered to be at very high surgical risk and was finally accepted by the Heart Team for transcatheter mitral valve implantation (TMVI) with the FORTIS transcatheter valve (Edwards Lifesciences, Irvine, California).

Author-supplied keywords

  • mitral regurgitation
  • transcatheter mitral valve implantation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Omar Abdul-Jawad Altisent

  • Eric Dumont

  • François Dagenais

  • Mario Sénéchal

  • Mathieu Bernier

  • Kim O'Connor

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free